Progressive metastatic disease is a major cause of mortality for patients diagnosed with multiple types of solid tumors. One of the long-term goals of our laboratory is to identify molecular interactions that regulate metastasis, as a basis for developing agents that inhibit this process. Toward this goal, we recently demonstrated that intercellular adhesion molecule-2 (ICAM-2) converted neuroblastoma (NB) cells from a metastatic to a non-metastatic phenotype, a previously unknown function for ICAM-2. Interestingly, ICAM-2 suppressed metastatic but not tumorigenic potential in preclinical models, supporting a novel mechanism of regulating metastasis. We hypothesized that the effects of ICAM-2 on NB cell phenotype depend on the interaction of ICAM-2 with the cytoskeletal linker protein α-actinin. The goal of the study presented here was to evaluate the impact of α-actinin binding to ICAM-2 on the phenotype of NB tumor cells. We used in silico approaches to examine the likelihood that the cytoplasmic domain of ICAM-2 binds directly to α-actinin. We then expressed variants of ICAM-2 with mutated α-actinin-binding domains, and compared the impact of ICAM-2 and each variant on NB cell adhesion, migration, anchorage-independent growth, co-precipitation with α-actinin and production of localized and disseminated tumors in vivo. The in vitro and in vivo characteristics of cells expressing ICAM-2 variants with modified α-actinin-binding domains differed from cells expressing ICAM-2 wild type (WT) and also from cells that expressed no detectable ICAM-2. Like the WT protein, ICAM-2 variants inhibited cell adhesion, migration and colony growth in vitro. However, unlike the WT protein, ICAM-2 variants did not completely suppress development of disseminated NB tumors in vivo. The data suggest the presence of α-actinin-dependent and α-actinin-independent mechanisms, and indicate that the interaction of ICAM-2 with α-actinin is critical to conferring an ICAM-2-mediated non-metastatic phenotype in NB cells.
INTRODUCTION
Intercellular adhesion molecule-2 (ICAM-2) is a transmembrane glycoprotein belonging to the immunoglobulin superfamily of cell adhesion molecules. 1, 2 When expressed by vascular endothelial cells, the extracellular domain of ICAM-2 binds to β 2 -integrins on the surface of leukocytes as an initial step in immune responses. 3, 4 When expressed by neovascular endothelium and leukocytes, the cytoplasmic domain (CD) of ICAM-2 binds to cytoskeletal linker proteins, but the functional significance of these interactions is not well understood. In tumor cells, we recently identified a unique role for ICAM-2 when we demonstrated that ICAM-2 conferred a non-metastatic phenotype in neuroblastoma (NB) cells. 5 SK-N-AS NB cells expressing ICAM-2 produced no tumors in an experimental metastasis model, whereas SK-N-AS cells expressing no detectable ICAM-2 produced disseminated tumors. Of note, the CD of ICAM-2 was essential to conferring a non-metastatic phenotype. The current study examines the hypothesis that the CD of ICAM-2 interacts with the cytoskeletal linker protein α-actinin and that this interaction is critical to the function of ICAM-2 in NB cells. We envision that identification of specific molecular interactions that regulate the metastatic process may provide a basis for development of antitumor agents that prevent or delay progressive metastatic disease in patients with solid tumors. We propose that the direct binding of the CD of ICAM-2 to α-actinin represents this type of regulatory interaction.
The sequence of ICAM-2 wild type (WT) expressed by normal cells 6, 7 and by NB cells is identical. The mature protein comprises a 202-amino-acid N-terminus extracellular domain with two immunoglobulin-like loop structures, and 26-amino-acid transmembrane domain and CD (Figure 1) . A 21-amino-acid signal peptide routes the nascent protein through the endoplasmic reticulum, but is not present in the mature protein. Multiple proteins bind to the extracellular domain and to the CD of ICAM-2. [8] [9] [10] [11] [12] [13] These protein interactions are thought to mediate outside-in or inside-out signaling across the cell membrane, but the biological significance of this signaling remains to be elucidated. What is well established is that the actin network is a primary regulator of cell motility, and that actin cytoskeletal linker proteins that associate with ICAM-2 (ezrin, radixin, moesin, α-actinin) 10, 12 have roles in inducing or suppressing tumorigenic and/or metastatic properties of tumor cells. [14] [15] [16] [17] Linker proteins are thought to 'connect' actin to the cell membrane, by binding simultaneously to actin and to membrane-bound cell adhesion molecules. The hypothesis to be tested in this study is that ICAM-2 suppresses NB cell motility and therefore metastatic potential by binding to the actin cytoskeletal linker protein α-actinin. We used in silico modeling to predict the likelihood that the CD of ICAM-2 binds directly to α-actinin, and functional assays to compare the phenotypes of NB cells transfected to express ICAM-2 WT or variants with no detectable interaction with α-actinin (mAB4 and mAB8). These variants are not expressed in situ, but were expressed in transfected cells to determine whether variants that retain overall ICAM-2 WT structure but do not associate with αactinin conferred the same phenotype as the WT protein.
RESULTS
We demonstrated previously that the CD of human ICAM-2, which contains a broadly defined α-actinin-binding sequence, 12 was essential to conferring a non-metastatic phenotype in NB cells. 5 We now show a high likelihood that the CD of ICAM-2 binds to EFhand domain of α-actinin and that this binding contributes to the phenotype of NB cells.
The three-dimensional structure of the α-actinin-binding domain of ICAM-2 WT likely differs from those of variants mAB4 and mAB8 We first modeled the α-actinin-binding subdomain for ICAM-2 WT and variants mAB4 and mAB8, predicting that each variant would have minimal interaction with α-actinin ( Figure 1a ). The variants differed from ICAM-2 WT by having four (mAB4) or eight (mAB8) of the eight amino acids comprising the proposed α-actininbinding domain of ICAM-2 scrambled, to limit interaction with αactinin. We then compared predicted structures for these forms of ICAM-2 in silico. Modeling was based on the known sequence and structure of the CD of murine ICAM-2, and accomplished by aligning amino acids 250-277 of the murine protein with amino acids 262-269 of human ICAM-2 WT, mAB4 and mAB8 (PDB 1J19 9 ). Resulting structures reflected a relative hydrophobic core (AAW) adjacent to hydrophilic amino acids (R) of ICAM-2 WT, compared with ICAM-2 mAB8, which contains a positively charged amino-acid cluster (RRR) surrounded by hydrophobic amino acids (WA). ICAM-2 mAB4 contains a mixture of hydrophilic and hydrophobic (AAR) at the same positions. Structures demonstrated marked contrasts among the three constructs ( Figure 1b ). Readily apparent was divergent orientation of tryptophan (W) in the variant peptides, even though this amino acid was displaced by only one position in the variants. ICAM-2 WT appeared to contain 'open' sites that might facilitate protein interactions. ICAM-2 mAB4 retained the side-chain spatial configuration of four amino acids compared with ICAM-2 WT (similar orientations in green), whereas ICAM-2 mAB8 retained the spatial configuration of none of these side chains. These data predict that the structures and therefore the functions of the two variants differed from ICAM-2 WT, suggesting that the proposed constructs were suitable for comparing the function of ICAM-2 WT with variants that interacted inefficiently with α-actinin.
Modeling reveals a likely high-affinity interaction between the CD of ICAM-2 and the EF-hand domain of α-actinin The region of α-actinin that binds to ICAM-2 has been only broadly defined. 12 To assess the likelihood that ICAM-2/α-actinin binding occurs in situ, it was necessary to identify a specific domain of α-actinin likely to interact with ICAM-2. We accomplished this using published structural data for full-length chicken α-actinin (PDB 1SJJ 18 ), the CD of murine ICAM-2 (PDB 1J19 9 ) and the co-structure of the EF-hand domain of human α-actinin with the α-actinin-binding domain of rabbit titin (PDB 1H8B 19 ). In a surface proposed α-actinin-binding domains of ICAM-2 WT, mAB4 and mAB8 were generated using PDB IJ19 and PyMol. 43 The predicted structure of this domain of ICAM-2 WT is in green. The amino-acid side chains of this domain of ICAM-2 mAB4 and mAB8 that have spatial orientations similar to those in the WT protein are also in green.
representation model of chicken α-actinin (PDB 1SJJ) (Figure 2a ), the EF-hand domain in the C-terminus (red) and the actin-binding domain in the N-terminus (blue) are evident. Clearly visible is a potential binding cleft (arrow) formed by the EF-hand domain and actin-binding domain of the protein. As chicken and human α-actinins are 87% identical, 18 we hypothesized that human α-actinin contains an analogous domain and that this domain is the site of interaction with human ICAM-2. Figure 2b shows the ribbon structure of the EF-hand domain of chicken α-actinin (red) and the actin-binding domain (blue). Aligned with the structure of chicken α-actinin is the EF-hand domain of human α-actinin (green). The structural alignment of these domains demonstrated an RMSD (root-mean-square deviation) of 1.47 Å 2 , indicating a high confidence alignment and a high likelihood that the three-dimensional structure of this domain of human α-actinin is similar to the known structure of chicken α-actinin.
Next, based on the known co-structure depicting the binding of rabbit titin with the EF-hand domain of human α-actinin, 19 we modeled the helical structure of titin ( Figure 2b ; arrow, residues 645-694) that interacts with α-actinin in its orientation relative to the EF-hand domain of human α-actinin. This procedure placed the helical α-actinin-binding domain in the 'binding pocket' of fulllength α-actinin suggested by the structure in Figure 2a . Notably, the conserved sequence of the α-actinin-binding domain of titin and the analogous domain of murine ICAM-2 (known structure) and human ICAM-2 (by sequence homology) ( Figure 2c ) suggested that the interaction of the CD of human ICAM-2 with α-actinin would be similar to the known binding of titin and α-actinin.
To further support this hypothesis, we aligned the surface structure of full-length chicken α-actinin with the α-actininbinding domain titin peptide (magenta) that is structurally conserved in murine ICAM-2 and human ICAM-2 ( Figure 2d ). This helical domain remained fitted into the proposed binding pocket of α-actinin. Specific residues of α-actinin (spheres, Figure 2e ) adjacent to the helix comprising the α-actinin-binding domain of titin include hydrophobic amino acids Val 825, Leu 848, Met 860, Phe 878, and Leu 882 of α-actinin. These residues comprise an available interactive domain for the interaction with hydrophobic cores of α-actinin-binding domains of titin and of murine and human ICAM-2.
Notably, the helical structure critical to the binding of titin with human α-actinin 19 and, independently, of murine ICAM-2 with human α-actinin appears to be a conserved aspect of these interactions. Of particular relevance, the original study describing the interaction between titin Z-repeats Zr1 and Zr7 of this helical domain and the EF-hand domain of α-actinin reported a nanomolar-binding affinity for the interaction. 19 Together, published data, Figures 1 and 2 , and the conserved sequence of the CDs of murine and human ICAM-2 suggest a high likelihood that the CD of human ICAM-2 interacts with high affinity to EF-hand domain of α-actinin, and that the structures of ICAM-2 mAB4 and mAB8 differ from ICAM-2 WT and alter the interaction of these variants with α-actinin.
To then examine the impact of ICAM-2/α-actinin interaction on NB cell phenotype, we first documented expression and cell membrane localization of ICAM-2 WT, mAB4 and mAB8 as alterations of CD have been reported to affect the subcellular localization of mutated proteins. [20] [21] [22] ICAM-2 localizes to cell membranes in transfected SK-N-AS NB cells The SK-N-AS cell line was derived from NB tumor cells in a bone marrow specimen obtained from a pediatric patient with Stage IV NB. This cell line is not MYCN-amplified and expresses no detectable endogenous ICAM-2. 5 We transfected these cells to express ICAM-2 WT, mAB4 or mAB8. Immunoblots (Figure 3a ) with antibodies to the extracellular N-terminus (AF244) or the intracellular C-terminus (sc-1512) of ICAM-2 confirmed its expression. Appropriately, only the antibody to the N-terminus of ICAM-2 detected ICAM-2 variants with scrambled CDs. Immunofluorescence analysis verified the cell membrane localization of ICAM-2 constructs (Figure 3b ). Vector-transfected SK-N-AS cells (Control) showed no detectable ICAM-2 expression.
ICAM-2 WT co-precipitated with α-actinin
We then used co-immunoprecipitation to address whether ICAM-2 with a partially (mAB4) or fully scrambled (mAB8) α-actinin-binding domain associated with α-actinin. We immunoprecipitated (IP) α-actinin and immunoblotted (IB) for ICAM-2. IP/IB results for positive (WT) and negative (Control) controls ( Figure 3c ) demonstrated that ICAM-2 WT associated with α-actinin. In contrast, IP/IB showed no detectable association of ICAM-2 mAB4 or mAB8 with α-actinin ( Figure 3d ). The data indicate that rearrangement of amino acids 262-269 of the WT protein minimized the ICAM-2/α-actinin interaction. We next evaluated the effects of ICAM-2 WT, mAB4 and mAB8 on cell phenotype. Figure 3 . ICAM-2 WT and variants localized to cell membranes. (a) Immunoblots confirmed that tranfected SK-N-AS cells expressed readily detectable levels of ICAM-2 WT, mAB4 or mAB8. Data in both membranes were generated in the same experiment but immunoblotted individually. (b) Immunofluorescence staining demonstrated that ICAM-2 WT, mAB4 and mAB8 localized to cell membranes. Scale bar represents 10 μm for all panels. Details of procedures used are in the 'Materials and methods'. (c, d) ICAM-2 WT, but not mAB4 and mAB8, co-precipitated with α-actinin. Immunoprecipitations (IP) were performed using whole-cell lysates and a mouse monoclonal antibody to α-actinin (MAB1682, Millipore-Fisher Scientific). The presence of all three types of ICAM-2 proteins in the 'input' whole-cell lysates was confirmed prior to IP.
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attached monolayers, had similar nascent neuronal morphology, were similar in size when detached (assessed by Coulter Counter sizing, not shown) and had equivalent doubling times (30.4 ± 4.7 h) ( Figure 4b ). All transfectants grew as tight cell groups. Groupings of ICAM-2 WT transfectants appeared more cohesive and angular than Control transfectants, as is sometimes characteristic of less aggressive phenotypes. 23 ICAM-2 inhibited NB cell adhesion to extracellular matrix (ECM) proteins, independent of the interaction with α-actinin Adhesive and migratory properties are critical determinants of the metastatic potential of tumor cells, 23, 24 with both processes involving a myriad of intracellular and extracellular proteins. Initial Matrigel invasion assays (Supplementary Figure S1 ) indicated that extracellular matrix (ECM) proteins might participate in the phenotype conferred by ICAM-2. To identify specific ECM proteins involved, we performed adhesion assays with fibronectin, collagen I or vitronectin. Control transfectants adhered equally well to all three ECM proteins ( Figure 5 ), and ICAM-2 WT, mAB4 and mAB8 inhibited adhesion to each of these proteins. Inhibition did not depend on the ICAM-2/α-actinin interaction, as both variants produced results equivalent to the WT protein.
ICAM-2 WT, mAB4 and mAB8 inhibited tumor cell motility in vitro and growth in soft agar, in an α-actinin-dependent manner We then used Boyden migration assays to evaluate whether fibronectin, collagen I or vitronectin impacted migration of NB cells expressing ICAM-2. Collagen I was the strongest chemoattractant of the ECM proteins ( Figure 6 ). Little migration was seen with vitronectin. All three ICAM-2 constructs inhibited migration mediated by fibronectin, indicating that this inhibition was independent of α-actinin. In contrast, ICAM-2 WT inihibited migration toward collagen I in an α-actinin-dependent manner. When collagen I was used as chemoattractant, ICAM-2 mAB4 and mAB8 conferred a phenotype intermediate to Control and ICAM-2 WT. Inclusion of antibody CBR IC2/2 3 (5 μg/ml), which inhibits extracellular binding of ICAM-2 to β 2 -integrin, had no effect on migration (data not shown). The data are consistent with the conclusion that the ICAM-2/α-actinin interaction contributes to ICAM-2-mediated migratory properties of NB cells, in the presence of specific ECM proteins.
ICAM-2 WT also inhibited anchorage-independent growth. As previously published, SK-N-AS cells expressing ICAM-2 WT formed smaller and fewer colonies in soft agar (9.3 ± 2.0) than control transfectants (297.2 ± 5.2 colonies) (Po0.0001) (Figures 7a and b ). 25 Cells expressing mAB4 and mAB8 variants also produced fewer colonies than Control cells (Po0.0001), but more than cells expressing ICAM-2 WT (P = 0.00135 and Po0.0001). ICAM-2 variants conferred a partial phenotype that was, like migration, affected by the association of ICAM-2 with α-actinin. To confirm that results seen were not unique to a single NB cell line, we also performed anchorage-independent growth assays with Control and ICAM-2 WT transfectants of NB-1691 cells (Supplementary Figure  S2A ). Unlike SK-N-AS cells NB-1691 cells have an amplified MYCN gene copy number, an unfavorable prognostic indicator clinically. As was seen with SK-N-AS cells, ICAM-2 inhibited the growth in soft agar of MYCN-amplified NB-1691 cells transfected to upregulate expression of ICAM-2; ICAM-2 was functional in MYCN-amplified (NB-1691) and non-amplified (SK-N-AS) NB cells.
Notably, the differences observed in anchorage-independent growth in vitro can reflect differences in tumorigenic or metastatic potential. 26, 27 Therefore, we evaluated production of localized (tumorigenic potential) and disseminated (metastatic potential) tumors in vivo.
ICAM-2 did not affect development of subcutaneous tumors (tumorigenic potential) by NB cells
We injected 5000 or 50 000 or 500 000 Control or ICAM-WT transfectants subcutaneously into SCID mice and observed the mice for tumor formation. When 500 000 cells were implanted, the two transfectants produced tumors of equivalent size 45 ± 7 days following implantation (Supplementary Figure S3 ). However, neither transfectant produced tumors within the >2-month duration of the experiment when 5000 or 50 000 cells were implanted. We detected no impact of ICAM-2 on the tumorigenicity of SK-N-AS NB cells.
ICAM-2 WT suppressed development of disseminated tumors in vivo (metastatic potential of NB cells): ICAM-2 mAB4 and mAB8 delayed, but did not completely suppress development of disseminated tumors
We demonstrated previously that ICAM-2 WT confers a nonmetastatic phenotype in an in vivo model of disseminated NB. Kaplan-Meier survival plots demonstrated that mice receiving Control cells intravenously (i.v.) (Figure 7c ) developed tumors at multiple anatomic sites, requiring euthanasia within 1-3 months. 25 Mice receiving ICAM-2 WT transfectants developed no detectable tumors and survived significantly longer (Po 0.0001 compared with Control). To first demonstrate that this function of ICAM-2 was not unique to a single cell line, we used the same model system to evaluate the function of ICAM-2 WT in NB-1691 cells. As was seen with SK-N-AS cells, upregulation of ICAM-2 suppressed development of disseminated tumors in SCID mice receiving i.v. injections of NB-1691 cell transfected to upregulate expression of ICAM-2 (Po 0.02) (Supplementary Figure S2C) . To then determine the extent to which the ICAM-2/α-actinin interaction affected the in vivo phenotype of NB cells, we injected i.v. SK-N-AS cells transfected to express ICAM-2 mAB4 or mAB8, and observed the mice for tumor development. Expression of ICAM-2 variants delayed but did not prevent development of disseminated tumors in vivo (Figure 7c ). Disseminated tumors developed in three mice receiving cells expressing the mAB4 variant and in nine mice receiving cells expressing the mAB8 variant. Survival data showed that mice receiving cells expressing ICAM-2 WT, mAB4 and mAB8 survived longer (P o0.0002) than mice receiving Control transfectants, and that mice receiving cells expressing ICAM-2 WT survived longer (P o 0.0001) than mice receiving cells expressing ICAM-2 mAB4 or mAB8 variants. Mutation of the α-actinin-binding domain of ICAM-2 attenuated the ability of ICAM-2 to suppress metastatic properties of NB cells. In vitro and in vivo data indicate that the α-actinin-binding domain of ICAM-2 contributes significantly to the function of ICAM-2 in NB cells. Taken together, the data suggest that ICAM-2 functions as a suppressor of metastasis rather than of tumorigenesis in NB cells.
DISCUSSION
Development of metastatic disease is associated with a high mortality for patients diagnosed with solid tumors. The long-term goal of our laboratory is to identify molecular interactions critical to the metastatic process, with an end goal of designing therapeutic agents that prevent metastatic progression. Our earlier work 5, 25 demonstrated that ICAM-2 completely suppressed development of disseminated NB tumors in an experimental metastasis model, and that the CD of ICAM-2 was essential for this function. The current study determined that direct binding of ICAM-2 to α-actinin is essential to suppress the metastatic potential of these tumor cells. Together, in silico, in vitro and in vivo data indicate a high likelihood that the intracellular Figure 5 . ICAM-2 WT and mAB variants inhibit NB cell adhesion to ECM proteins. (a) NB cells adherent to each ECM protein were imaged after staining. The optical density for Control cells (used in calculations and presented as 100%) were for fibronectin = 0.5630 ± 0.0032, for collagen I = 0.4855 ± 0.019 and for vitronectin = 0.4443 ± 0.0160 (mean ± s.e.m.), as shown in right panel. (b) NB cell adhesion was quantitated by determination of the optical density of crystal violet-stained, adherent cells by standard methods. 44 Values for ICAM-2 transfectants were significantly different from Control transfectants (**Po 0.001 or ***P o0.0001, as indicated).
C-terminus of ICAM-2 interacts directly with the EF-hand domain of α-actinin to regulate tumor cell migration mediated by collagen I, anchorage-independent growth and development of disseminated tumors in vivo. These studies are the first to model the interaction of α-actinin with a membrane-bound CAM. They predict that ICAM-2 interacts with α-actinin predominantly through hydrophobic residues (Figure 2e) , in contrast to the hydrophilic or neutral interactions reported for α-actinin with ICAM-1, ICAM-5 or β1-integrin ( Figure 8 ). The data also suggest a second, α-actinin-independent mechanism by which ICAM-2 inhibits adhesion to or migration mediated by specific ECM proteins. Neither mechanism for ICAM-2 has been reported previously.
The most well-studied functions for ICAM-2 are immune-related: ICAM-2 enhanced the immune response of transfected colon carcinoma cells; 28 induced an antitumor immune response in pancreatic carcinogenesis 29 and contributed to cytolysis of human pancreatic cancer cells by human γδ-T cells. 30 ICAM-2 also rendered transfected Jurkat T cells less sensitive to the cytotoxicity of staurosporine and anti-Fas antibody; 31 but did not change the sensitivity of NB cells to doxorubicin, vincristine or etoposide (KJY, unpublished data). We propose that ICAM-2 has a function in NB cells that is distinct from functions previously described for this protein. Unpublished data from our laboratory indicate that ICAM-2 may have functions similar to those in NB in other types of solid tumors, including pancreatic and breast cancer cells.
Although the data strongly suggest α-actinin-dependent and -independent mechanisms, some limited (undetectable) interaction may occur between the ICAM-2 variants and α-actinin to suppress adhesion to fibronectin and collagen I, and to confer partial phenotypes in growth in soft agar and migration assays and in disseminated tumor production in vivo. The data are also consistent with multiple mechanistic possibilities. First, intracellular ICAM-2/α-actinin binding may induce conformational changes in the extracellular domain of the same ICAM-2 molecule to inhibit or facilitate cellular interactions with ECM proteins, a type of inside-out signaling as has been reported for β1and β 2 -integrin and ICAM-1. [32] [33] [34] Second, effects of ICAM-2 on NB cell adhesion and migration may be more indirect. Although immunoblots show no effect of ICAM-2 on level of expression of α 5 -, α 2 -or β1-integrin proteins in NB cells (data not shown), ICAM-2 may affect the function of these components of binding partners of fibronectin (α 5 β 1 ) and collagen I (α 2 β 1 ) ( Figures 5 and 6 ). Thirdly, unpublished RNA microarray data (not shown) demonstrate that ICAM-2 upregulated expression of at least three phosphatases (~three-to sevenfold) that dephosphorylate focal adhesion kinase, Src, and Rac and Rho GTPases, each of which has a critical role in tumor cell motility. Less likely is the possibility that ICAM-2 induces tumor cell differentiation or de-differentiation, as RT-PCR data (Supplementary Figure S4 ) and immunoblot data (not shown) reveal no differences in expression of EMT (E-cadherin, Occludin, Vimentin, Snail 1) or stemness (c-Myc) markers. Morphology (Figure 4 ) and tumorigenicity data (Supplementary Figure S3 ) are consistent with this observation.
The data indicate that ICAM-2 inhibits adhesive and migratory properties of tumor cells by two distinct mechansims, but is unlikely to affect NB cell differentiation or tumorigenicity. Further, ICAM-2/α-actinin binding is essential to the function of ICAM-2 in NB cells.
MATERIALS AND METHODS

Cell lines
The parent human NB cell line SK-N-AS (American Type Culture Collection, Manassas, VA, USA) and transfectants were maintained in Dulbecco's Modified Eagle Medium (DMEM) (Hyclone, Fisher Scientific, Savannah, GA, USA) with 10% fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA, USA) and 2 mM L-glutamine (Fisher Scientific, Savannah, GA, USA) at 37°C, 10% CO 2 .
Molecular models of ICAM-2/α-actinin binding
Modeling studies were based on published structural data (Protein Data Base (PDB1ZXQ and PDB1J19 for ICAM-2; PDB1HCI, PDB 1SJJ and PDB1H8B for α-actinin)). Molecular dynamics simulations using AMBER 99 force-field distribution was used to assess the flexibility 35 of energy-minimized structures. Overall structural quality was evaluated with PROCHECK, 36 Verify3Dimensional 37 and MolProbity servers. Structures were evaluated by Ramachandran analysis, rotamer analysis, bond length, angle geometry and clash analysis. Structures having MolProbity scores of 50% or better were deemed of sufficient quality for docking studies, as templates for protein modeling (Global Range Molecular Matching), 38 and for evaluating compensatory surface changes.
ICAM-2 variants
The plasmid encoding human ICAM-2 and transfectants were generated as published. 5 
Anchorage-independent growth
The assays were done as published previously. 5, 25 IP Co-immunoprecipitations were done by standard methods as described previously. 5, 25 The antibody for IP of α-actinin was MAB1682 (Fisher Scientific). Antibodies for IB of ICAM-2, α-actinin and actin were AF244 (R&D Systems, Minneapolis, MN, USA) and sc-1512 (Santa Cruz Biotech, Figure 7 . ICAM-2 inhibited colony growth in soft agar and development of disseminated tumors in vivo. ICAM-2 mAB8 delayed but did not inhibit development of disseminated tumors in an in vivo model of metastatic NB. (a) ICAM-2 WT, mAB4 and mAB8 suppressed anchorage-independent growth in vitro. Colonies of >20 cells were visualized 14-21 days after plating. Results were quantitated manually and analyzed using a two-tailed t-test and GraphPad Prism software (*P = 0.0135 and ***P o0.0001). (b) Photomicrographs of representative colonies for Control and ICAM-2 WT transfectants were acquired at x400 magnification using a Dr-5 digital camera (Southern Microscope) mounted to a Nikon Eclipse TS100 inverted microscope and archived with TSView software (version 7.1.04, Tucsen Imaging Technology Co./ Southern Microscope). (c) Kaplan-Meier survival plots of mice that received i.v. injections of SK-N-AS cell transfectants were analyzed by log-rank (Mantel-Cox) test using GraphPad Prism 5 software (Version 5.02) and showed that mice receiving cells expressing mAB variants survived longer than mice receiving cells expressing no detectable ICAM-2, but not as long as mice receiving cells expressing ICAM-2 WT. *Data for control transfectants were previously published in BMC Cancer by BioMed Central. 25 Reprinted with permission. Figure 8 . Disparate α-actinin-binding sequences in proteins belonging to two families of cell adhesion molecules: ICAM-1, 45 ICAM-2, 12 ICAM-5 40 and β1-integrin. 46 Residues are indicated as hydrophobic (red), basic hydrophilic (blue), acidic hydrophilic (green) and neutral (black). 
Immunofluorescence staining
Immunofluorescence staining was performed using standard methods 12, 40 to visualize the distribution of ICAM-2 in situ. Plated cells were washed and fixed with cold methanol. Nonspecific binding was blocked by using 10% goat serum (Sigma 
Boyden chamber migration
Neuroblastoma cells were tryspsinized and suspended in serum-free DMEM at 3 × 10 5 cells/ml. In total, 100 μl of cell suspension added to the upper chamber of 6.5 mm transwell permeable supports (8 μm pore size). If included, CBR IC2/2 antibody was added to the cell suspension at 5 μg/ml. Lower chambers contained serum-free DMEM with 10 μg/ml of human collagen I (BD Biosciences, San Jose, CA, USA), plasma fibronectin (BD Biosciences) or plasma vitronectin (Promega, Madison, WI, USA). After an 18-h incubation, cells adherent to the membrane were fixed with 4% formaldehyde and stained with 0.02% crystal violet. Cells remaining on the apical side of the membrane were removed with cotton-tipped applicators, and photomicrographs of migratory cells attached to basal side of membrane were acquired and quantified manually. Image acquisition was with a Zeiss Axio Observer Z.1 microscope and ZEN 2011 Blue software.
Adhesion
In total, 96-well plates (Corning, Lowell, MA, USA) were coated for 2 h at room temperature with 10 μg/ml human collagen I (BD Biosciences), plasma fibronectin (BD Biosciences) or plasma vitronectin (Promega). After 2 h, ECM protein solutions were aspirated, wells were washed twice with phosphate-buffered saline and cells were incubated with 2% bovine serum albumin for 30 min at 37°C to limit nonspecific binding. Wells were then washed with serum-free DMEM, and each well was plated with 100 μl of NB cells suspended in serum-free DMEM at 3 × 10 5 cells/ml. Plates were centrifuged at 10 g for 1 min and incubated at 37°C, 10% CO 2 for 20 min. Nonadherent cells were removed by washing the plates two times with phosphate-buffered saline. Adherent cells were fixed with 4% formaldehyde, stained with 0.02% crystal violet and photomicrographs were acquired. Absorbances were recorded with a VersaMax microplate reader at 590 nm (Molecular Devices, LLC. Sunnyvale, CA, USA).
Mouse model of metastatic NB
This method has been reported in detail. 5, 25 Briefly, female Es1 e /SCID mice (6-8 weeks old), obtained from Dr Phil Potter, 41 were housed in AAALAC accredited vivariums at St Jude Children's Research Hospital Animal Resources Center (Memphis, TN, USA) or the University of Alabama at Birmingham (Birmingham, AL, USA). Protocols were approved by the St Jude or UAB Animal Care and Use Committee, respectively. Following i.v. injection of tumor cells, mice (10/group) were monitored daily and euthanized immediately if distress or discomfort was evident. Day of euthanasia was recorded as the day of death. Following subcutaneous injections, mice (3/group) were euthanized when tumors reached a volume of 1000-1500 mm 3 , calculated by standard methods. 42 
Statistical analyses
Statistical analyses were performed and graphs generated using GraphPad Prism software 5 (GraphPad, San Diego, CA, USA). Each type of assay was done a minimum of three times, with a minimum of three replicates per cell line. Kaplan-Meier survival data were analyzed using a log-rank test (Mantel-Haenszel).
ABBREVIATIONS
3D, three-dimensional; CAM, cell adhesion molecules; CD, cytoplasmic domain; ED, extracellular domain; IB, immunoblot; ICAM-2, Intercellular adhesion molecule-2; IP, immunoprecipitation; i.v., intravenous; mAB4, ICAM-2 with partially scrambled α-actinin binding domain; mAB8, ICAM-2 with fully scrambled α-actinin binding domain; NB, neuroblastoma; RMSD, root-mean-square deviation; s.c., subcutaneous; sp, signal peptide; TD, transmembrane domain; WT, wild type.
